AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|AAPL329.26+2.67 (+0.82%) ▲|ABBV255.55+2.17 (+0.86%) ▲|ABT100.86-0.81 (-0.79%) ▼|ACN141.15-3.59 (-2.48%) ▼|ADBE227.00-7.74 (-3.30%) ▼|AMAT565.50+39.80 (+7.57%) ▲|AMD535.45+31.88 (+6.33%) ▲|AMGN363.86-0.31 (-0.09%) ▼|AMT164.83-2.24 (-1.34%) ▼|AMZN247.42-2.57 (-1.03%) ▼|AVGO386.53+8.37 (+2.21%) ▲|AXP351.58-0.36 (-0.10%) ▼|BA210.55+1.07 (+0.51%) ▲|BAC61.37+0.95 (+1.56%) ▲|BKNG177.31-2.14 (-1.19%) ▼|BLK1,053.64-0.48 (-0.05%) ▼|BMY60.48+0.32 (+0.52%) ▲|BNY158.51+1.58 (+1.01%) ▲|BRK-B490.29-0.96 (-0.20%) ▼|C133.18+4.46 (+3.46%) ▲|CAT891.56+27.26 (+3.15%) ▲|CL90.20-1.74 (-1.89%) ▼|CMCSA23.69-0.10 (-0.40%) ▼|COF206.01-0.77 (-0.37%) ▼|COP116.99+1.31 (+1.13%) ▲|COST928.96-6.84 (-0.73%) ▼|CRM169.96-3.83 (-2.20%) ▼|CSCO111.18+0.48 (+0.43%) ▲|CVS109.45+1.84 (+1.71%) ▲|CVX190.07+0.36 (+0.19%) ▲|DE593.14+7.14 (+1.22%) ▲|DHR174.59-26.53 (-13.19%) ▼|DIS96.53+0.12 (+0.12%) ▲|DUK125.08-0.77 (-0.61%) ▼|EMR139.51+2.93 (+2.15%) ▲|FDX314.61+8.39 (+2.74%) ▲|GD370.74+0.14 (+0.04%) ▲|GE342.27+0.97 (+0.28%) ▲|GEV1,089.99+10.81 (+1.00%) ▲|GILD129.68-3.53 (-2.65%) ▼|GM78.91+3.11 (+4.10%) ▲|GOOG348.66-2.71 (-0.77%) ▼|GOOGL349.28-2.71 (-0.77%) ▼|GS1,080.93+25.90 (+2.45%) ▲|HD331.80-1.24 (-0.37%) ▼|HON231.64+5.46 (+2.41%) ▲|IBM211.01-1.99 (-0.93%) ▼|INTC104.36+7.30 (+7.52%) ▲|INTU289.56-4.26 (-1.45%) ▼|ISRG356.94+3.77 (+1.07%) ▲|JNJ250.61+1.79 (+0.72%) ▲|JPM344.94+6.07 (+1.79%) ▲|KO82.03-0.09 (-0.11%) ▼|LIN505.31-6.74 (-1.32%) ▼|LLY1,162.85+15.95 (+1.39%) ▲|LMT505.53-4.01 (-0.79%) ▼|LOW203.87-0.85 (-0.41%) ▼|LRCX322.12+15.36 (+5.01%) ▲|MA541.38-6.07 (-1.11%) ▼|MCD264.64-3.00 (-1.12%) ▼|MDLZ59.68-0.59 (-0.98%) ▼|MDT82.64-0.65 (-0.78%) ▼|META647.27+1.42 (+0.22%) ▲|MMM172.69+13.58 (+8.54%) ▲|MO73.48-1.18 (-1.58%) ▼|MRK125.55+1.15 (+0.92%) ▲|MS215.95+5.01 (+2.38%) ▲|MSFT397.87-4.43 (-1.10%) ▼|MU969.77+104.31 (+12.05%) ▲|NEE87.81-0.20 (-0.22%) ▼|NFLX66.85-0.75 (-1.11%) ▼|NKE43.26-0.22 (-0.49%) ▼|NOW102.24-2.46 (-2.35%) ▼|NVDA205.70+2.42 (+1.19%) ▲|ORCL125.49+4.11 (+3.38%) ▲|PEP134.61-0.86 (-0.63%) ▼|PFE24.89+0.14 (+0.55%) ▲|PG147.55-1.58 (-1.06%) ▼|PLTR133.37-1.48 (-1.10%) ▼|PM190.51-2.21 (-1.15%) ▼|QCOM174.23+3.91 (+2.30%) ▲|RTX196.40+1.96 (+1.01%) ▲|SBUX104.96+0.15 (+0.14%) ▲|SCHW102.57+0.03 (+0.03%) ▲|SO93.55-0.91 (-0.96%) ▼|SPG227.93-0.27 (-0.12%) ▼|T21.99+0.04 (+0.18%) ▲|TMO518.64-7.60 (-1.44%) ▼|TMUS191.19-4.45 (-2.27%) ▼|TSLA380.96+11.39 (+3.08%) ▲|TXN294.51+10.44 (+3.68%) ▲|UBER71.53-0.65 (-0.89%) ▼|UNH433.68+12.13 (+2.88%) ▲|UNP294.85-1.40 (-0.47%) ▼|UPS116.08+2.93 (+2.59%) ▲|USB63.45+0.31 (+0.48%) ▲|V358.32-2.25 (-0.62%) ▼|VZ43.37-0.14 (-0.31%) ▼|WFC87.89+1.56 (+1.80%) ▲|WMT110.29-1.91 (-1.70%) ▼|XOM150.97+2.61 (+1.76%) ▲|
24.8 C
New York
Tuesday, July 21, 2026

Tag: Amgen

BCC Research Releases 2024 Protein Synthesis Research Review

"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...

BCC Research Releases 2024 Protein Synthesis Research Review

"Driving Innovation and Sustainability: The Vital Role of Protein Synthesis in Modern Biotechnology and Its Impact on Chronic Disease Treatment, Technological Advances, and Market...

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies

Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics’ proprietary OGAP®-Verify discovery platform

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

Cancer Therapeutics Market Forecast to Reach $168 Billion by 2029, Highlighting Recurrent and Metastatic Innovations

"Metastatic Cancer: A Significant Therapeutic Challenge as Pharmaceutical Companies Leverage Digital Platforms and Data to Enhance Engagement with Patients, Providers, and Regulators in the...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsight

The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAmgen